Cargando…

Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines

BACKGROUND: The clinical efficacy of camptothecin (CPT), a drug specifically targeting topoisomerase I (TopoI), is under evaluation for the treatment of malignant gliomas. Due to the high unresponsiveness of these tumours to chemotherapy, it would be very important to study the signalling network th...

Descripción completa

Detalles Bibliográficos
Autores principales: Morandi, Elena, Severini, Cinzia, Quercioli, Daniele, D'Ario, Giovanni, Perdichizzi, Stefania, Capri, Miriam, Farruggia, Giovanna, Mascolo, Maria Grazia, Horn, Wolfango, Vaccari, Monica, Serra, Roberto, Colacci, Annamaria, Silingardi, Paola
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556695/
https://www.ncbi.nlm.nih.gov/pubmed/18694480
http://dx.doi.org/10.1186/1476-4598-7-66
_version_ 1782159588262412288
author Morandi, Elena
Severini, Cinzia
Quercioli, Daniele
D'Ario, Giovanni
Perdichizzi, Stefania
Capri, Miriam
Farruggia, Giovanna
Mascolo, Maria Grazia
Horn, Wolfango
Vaccari, Monica
Serra, Roberto
Colacci, Annamaria
Silingardi, Paola
author_facet Morandi, Elena
Severini, Cinzia
Quercioli, Daniele
D'Ario, Giovanni
Perdichizzi, Stefania
Capri, Miriam
Farruggia, Giovanna
Mascolo, Maria Grazia
Horn, Wolfango
Vaccari, Monica
Serra, Roberto
Colacci, Annamaria
Silingardi, Paola
author_sort Morandi, Elena
collection PubMed
description BACKGROUND: The clinical efficacy of camptothecin (CPT), a drug specifically targeting topoisomerase I (TopoI), is under evaluation for the treatment of malignant gliomas. Due to the high unresponsiveness of these tumours to chemotherapy, it would be very important to study the signalling network that drives camptothecin outcome in this type of cancer cells. To address this issue, we had previously compared the expression profile of human U87-MG glioblastoma cells with that of a CPT-resistant counterpart, giving evidence that the development of a robust inflammatory response was the main transcriptional effect associated with CPT resistance. Here we report time-related changes and cell line specific patterns of gene expression after CPT treatment by using two p53 wild-type glioblastoma cell lines, U87-MG and DBTRG-05, with different sensitivities to TopoI inhibition. RESULTS: First, we demonstrated that CPT treatment brings the two cell lines to completely different outcomes: accelerated senescence in U87-MG and apoptosis in DBTRG-05 cells. Then, to understand the different susceptibility to CPT, we used oligo-microarray to identify the genes whose expression was regulated during a time-course treatment, ranging from 2 h to 72 h. The statistical analysis of microarray data by MAANOVA (MicroArray ANalysis Of VAriance) showed much less modulated genes in apoptotic DBTRG-05 cells (155) with respect to the senescent U87-MG cells (3168), where the number of down-regulated genes largely exceeded that of the up-regulated ones (80% vs. 20%). Despite this great difference, the two data-sets showed a large overlapping (60% circa) mainly due to the expression of early stress responsive genes. The use of High-Throughput GoMINER and EASE tools, for functional analysis of significantly enriched GO terms, highlighted common cellular processes and showed that U87-MG and DBTRG-05 cells shared many GO terms, which are related to the down-regulation of cell cycle and mitosis and to the up-regulation of cell growth inhibition and DNA damage. Furthermore, the down-regulation of MYC and DP1 genes, which act as key transcription factors in cell growth control, together with the inhibition of BUB1, BUB3 and MAD2 mRNAs, which are known to be involved in the spindle checkpoint pathway, were specifically associated with the execution of senescence in U87-MG cells and addressed as critical factors that could drive the choice between different CPT-inducible effectors programs. In U87-MG cells we also found inflammation response and IL1-beta induction, as late transcriptional effects of Topo I treatment but these changes were only partially involved in the senescence development, as shown by IL1-beta gene silencing. CONCLUSION: By comparing the transcription profile of two glioblastoma cell lines treated with camptothecin, we were able to identify the common cellular pathways activated upon Topo I inhibition. Moreover, our results helped in identifying some key genes whose expression seemed to be associated with the execution of senescence or apoptosis in U87-MG and DBTRG-05 cells, respectively.
format Text
id pubmed-2556695
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25566952008-10-01 Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines Morandi, Elena Severini, Cinzia Quercioli, Daniele D'Ario, Giovanni Perdichizzi, Stefania Capri, Miriam Farruggia, Giovanna Mascolo, Maria Grazia Horn, Wolfango Vaccari, Monica Serra, Roberto Colacci, Annamaria Silingardi, Paola Mol Cancer Research BACKGROUND: The clinical efficacy of camptothecin (CPT), a drug specifically targeting topoisomerase I (TopoI), is under evaluation for the treatment of malignant gliomas. Due to the high unresponsiveness of these tumours to chemotherapy, it would be very important to study the signalling network that drives camptothecin outcome in this type of cancer cells. To address this issue, we had previously compared the expression profile of human U87-MG glioblastoma cells with that of a CPT-resistant counterpart, giving evidence that the development of a robust inflammatory response was the main transcriptional effect associated with CPT resistance. Here we report time-related changes and cell line specific patterns of gene expression after CPT treatment by using two p53 wild-type glioblastoma cell lines, U87-MG and DBTRG-05, with different sensitivities to TopoI inhibition. RESULTS: First, we demonstrated that CPT treatment brings the two cell lines to completely different outcomes: accelerated senescence in U87-MG and apoptosis in DBTRG-05 cells. Then, to understand the different susceptibility to CPT, we used oligo-microarray to identify the genes whose expression was regulated during a time-course treatment, ranging from 2 h to 72 h. The statistical analysis of microarray data by MAANOVA (MicroArray ANalysis Of VAriance) showed much less modulated genes in apoptotic DBTRG-05 cells (155) with respect to the senescent U87-MG cells (3168), where the number of down-regulated genes largely exceeded that of the up-regulated ones (80% vs. 20%). Despite this great difference, the two data-sets showed a large overlapping (60% circa) mainly due to the expression of early stress responsive genes. The use of High-Throughput GoMINER and EASE tools, for functional analysis of significantly enriched GO terms, highlighted common cellular processes and showed that U87-MG and DBTRG-05 cells shared many GO terms, which are related to the down-regulation of cell cycle and mitosis and to the up-regulation of cell growth inhibition and DNA damage. Furthermore, the down-regulation of MYC and DP1 genes, which act as key transcription factors in cell growth control, together with the inhibition of BUB1, BUB3 and MAD2 mRNAs, which are known to be involved in the spindle checkpoint pathway, were specifically associated with the execution of senescence in U87-MG cells and addressed as critical factors that could drive the choice between different CPT-inducible effectors programs. In U87-MG cells we also found inflammation response and IL1-beta induction, as late transcriptional effects of Topo I treatment but these changes were only partially involved in the senescence development, as shown by IL1-beta gene silencing. CONCLUSION: By comparing the transcription profile of two glioblastoma cell lines treated with camptothecin, we were able to identify the common cellular pathways activated upon Topo I inhibition. Moreover, our results helped in identifying some key genes whose expression seemed to be associated with the execution of senescence or apoptosis in U87-MG and DBTRG-05 cells, respectively. BioMed Central 2008-08-11 /pmc/articles/PMC2556695/ /pubmed/18694480 http://dx.doi.org/10.1186/1476-4598-7-66 Text en Copyright © 2008 Morandi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Morandi, Elena
Severini, Cinzia
Quercioli, Daniele
D'Ario, Giovanni
Perdichizzi, Stefania
Capri, Miriam
Farruggia, Giovanna
Mascolo, Maria Grazia
Horn, Wolfango
Vaccari, Monica
Serra, Roberto
Colacci, Annamaria
Silingardi, Paola
Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title_full Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title_fullStr Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title_full_unstemmed Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title_short Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines
title_sort gene expression time-series analysis of camptothecin effects in u87-mg and dbtrg-05 glioblastoma cell lines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556695/
https://www.ncbi.nlm.nih.gov/pubmed/18694480
http://dx.doi.org/10.1186/1476-4598-7-66
work_keys_str_mv AT morandielena geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT severinicinzia geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT querciolidaniele geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT dariogiovanni geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT perdichizzistefania geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT caprimiriam geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT farruggiagiovanna geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT mascolomariagrazia geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT hornwolfango geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT vaccarimonica geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT serraroberto geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT colacciannamaria geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines
AT silingardipaola geneexpressiontimeseriesanalysisofcamptothecineffectsinu87mganddbtrg05glioblastomacelllines